These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 8366183)

  • 1. Effects of one year of treatment with pravastatin, an HMG-CoA reductase inhibitor, on lipoprotein a.
    Hunninghake DB; Stein EA; Mellies MJ
    J Clin Pharmacol; 1993 Jun; 33(6):574-80. PubMed ID: 8366183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia.
    Cheung MC; Austin MA; Moulin P; Wolf AC; Cryer D; Knopp RH
    Atherosclerosis; 1993 Aug; 102(1):107-19. PubMed ID: 8257447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum Lp(a) concentrations are unaffected by treatment with the HMG-CoA reductase inhibitor Pravastatin: results of a 2-year investigation.
    Fieseler HG; Armstrong VW; Wieland E; Thiery J; Schütz E; Walli AK; Seidel D
    Clin Chim Acta; 1991 Dec; 204(1-3):291-300. PubMed ID: 1840246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of pravastatin, an HMG CoA reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by their apolipoprotein composition.
    Bard JM; Parra HJ; Douste-Blazy P; Fruchart JC
    Metabolism; 1990 Mar; 39(3):269-73. PubMed ID: 2106607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of pravastatin on plasma lipoprotein and apolipoprotein levels in primary hypercholesterolemia. The Southeastern Michigan Collaborative Group.
    Rubenfire M; Maciejko JJ; Blevins RD; Orringer C; Kobylak L; Rosman H
    Arch Intern Med; 1991 Nov; 151(11):2234-40. PubMed ID: 1953228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of fluvastatin and pravastatin on lipid profiles and thromboxane production in type IIa hypercholesterolemia.
    Milani M; Cimminiello C; Merlo B; Lorena M; Arpaia G; Bonfardeci G
    Am J Cardiol; 1995 Jul; 76(2):51A-53A. PubMed ID: 7604798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Central nervous system effects of HMG CoA reductase inhibitors: lovastatin and pravastatin on sleep and cognitive performance in patients with hypercholesterolemia.
    Kostis JB; Rosen RC; Wilson AC
    J Clin Pharmacol; 1994 Oct; 34(10):989-96. PubMed ID: 7836550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. I. A dose-response study.
    Hunninghake DB; Knopp RH; Schonfeld G; Goldberg AC; Brown WV; Schaefer EJ; Margolis S; Dobs AS; Mellies MJ; Insull W
    Atherosclerosis; 1990 Nov; 85(1):81-9. PubMed ID: 2126437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apolipoprotein(a) polymorphism predicts the increase of Lp(a) by pravastatin in patients with familial hypercholesterolaemia treated with bile acid sequestration.
    Klausen IC; Gerdes LU; Meinertz H; Hansen FA; Faergeman O
    Eur J Clin Invest; 1993 Apr; 23(4):240-5. PubMed ID: 8500516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of pravastatin on serum lipids, apolipoproteins and lipoprotein (a) in patients with non-insulin dependent diabetes mellitus.
    Umeda F; Watanabe J; Inoue K; Hisatomi A; Mimura K; Yamauchi T; Sako Y; Kunisaki M; Tajiri Y; Nawata H
    Endocrinol Jpn; 1992 Feb; 39(1):45-50. PubMed ID: 1535040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of cholesterol-lowering on plasma membrane lipids and function.
    Lijnen P; Echevaría-Vázquez D; Petrov V
    Methods Find Exp Clin Pharmacol; 1996 Mar; 18(2):123-36. PubMed ID: 8740244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effects of pravastatin on serum lipids, apoproteins, and lipoprotein (a) in primary hypercholesterolemia].
    Galetta F; Sampietro T; Basta G; Bionda A
    Minerva Med; 1994 Jun; 85(6):321-6. PubMed ID: 8084435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pravastatin effects on lipoproteins, Lp (a), apo B and apo A-1 in patients with primary hypercholesterolemia].
    Novazzi JP; Fonseca FA; Feres MC; da Silva RC; Lima JC; Martinez TL
    Arq Bras Cardiol; 1994 Jun; 62(6):395-8. PubMed ID: 7826229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial.
    Lewis JH; Mortensen ME; Zweig S; Fusco MJ; Medoff JR; Belder R;
    Hepatology; 2007 Nov; 46(5):1453-63. PubMed ID: 17668878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetic study of statin therapy and cholesterol reduction.
    Chasman DI; Posada D; Subrahmanyan L; Cook NR; Stanton VP; Ridker PM
    JAMA; 2004 Jun; 291(23):2821-7. PubMed ID: 15199031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of fluvastatin versus pravastatin treatment of primary hypercholesterolemia. French Fluvastatin Study Group.
    Jacotot B; Benghozi R; Pfister P; Holmes D
    Am J Cardiol; 1995 Jul; 76(2):54A-56A. PubMed ID: 7604799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pravastatin vs. probucol in the treatment of hypercholesterolemia. A double-blind study].
    Sienra-Pérez JC; Lerman-Garber I; Ahumada-Ayala M; Castañón-Romo C; Cardoso-Saldaña G; Laguna-Castellanos M; Posadas-Romero C
    Arch Inst Cardiol Mex; 1991; 61(4):365-73. PubMed ID: 1953212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health-related quality of life and long-term therapy with pravastatin and tocopherol (vitamin E) in older adults.
    Carlsson CM; Papcke-Benson K; Carnes M; McBride PE; Stein JH
    Drugs Aging; 2002; 19(10):793-805. PubMed ID: 12390056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
    Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM
    Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia. Pravastatin Multicenter Study Group II.
    Arch Intern Med; 1993 Jun; 153(11):1321-9. PubMed ID: 8507122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.